文献速递神经免疫认知障碍与痴呆

血清神经丝轻链:多发性硬化神经元损伤的生物标志物

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
PubMed 文献 · Ann Neurol · 2017-01-01

研究评估超灵敏单分子阵列检测的血清神经丝轻链(sNfL)在多发性硬化(MS)中的价值。结果显示sNfL在MS患者中高于健康对照,与脑脊液NfL、钆增强病灶、EDSS和复发相关,且治疗下降低;高于健康对照百分位者未来复发和EDSS恶化风险更高。

要点

  • sNfL在MS患者中高于健康对照,与脑脊液NfL强相关。
  • sNfL与钆增强病灶、EDSS和复发独立相关,治疗下降低。
  • sNfL高于健康对照97.5百分位者复发和EDSS恶化风险更高。

核心结论

  • sNfL可作为监测MS组织损伤和治疗效果的敏感且具临床意义的血液生物标志物。

研究设计与样本

  • 横断面研究纳入健康对照254例和MS患者142例(配对血清和脑脊液样本)。
  • 纵向研究纳入MS患者246例,中位随访3.1年(IQR=2.0-4.0)。

主要发现

  • 两个MS队列的sNfL水平均高于健康对照(p<0.001)。
  • 脑脊液NfL与sNfL强相关(β=0.589,p<0.001)。
  • 仅有脑或脊髓钆增强病灶者sNfL为43.4pg/ml(IQR=25.2-65.3),脑和脊髓均有病灶者为62.5pg/ml(IQR=42.7-71.4),均高于无病灶者29.6pg/ml(IQR=20.9-41.8)。
  • sNfL与EDSS评估(β=1.105,p<0.001)和复发(β=1.430,p<0.001)独立相关;疾病修饰治疗下sNfL较低(β=0.818,p=0.003)。
  • sNfL高于健康对照97.5百分位者复发风险增加(发生率比=1.94,95%CI=1.21-3.10,p=0.006),EDSS恶化风险增加(OR=2.41,95%CI=1.07-5.42,p=0.034)。

临床怎么用

  • 可考虑将sNfL作为MS疾病活动度和治疗反应的血液监测指标。
  • sNfL高于健康对照97.5百分位提示未来复发和残疾进展风险较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Neurofilament light chains (NfL) are unique to neuronal cells, are shed to the cerebrospinal fluid (CSF), and are detectable at low concentrations in peripheral blood. Various diseases causing neuronal damage have resulted in elevated CSF concentrations. We explored the value of an ultrasensitive single-molecule array (Simoa) serum NfL (sNfL) assay in multiple sclerosis (MS). METHODS: sNfL levels were measured in healthy controls (HC, n = 254) and two independent MS cohorts: (1) cross-sectional with paired serum and CSF samples (n = 142), and (2) longitudinal with repeated serum sampling (n = 246, median follow-up = 3.1 years, interquartile range [IQR] = 2.0-4.0). We assessed their relation to concurrent clinical, imaging, and treatment parameters and to future clinical outcomes. RESULTS: sNfL levels were higher in both MS cohorts than in HC (p < 0.001). We found a strong association between CSF NfL and sNfL (β = 0.589, p < 0.001). Patients with either brain or spinal (43.4pg/ml, IQR = 25.2-65.3) or both brain and spinal gadolinium-enhancing lesions (62.5pg/ml, IQR = 42.7-71.4) had higher sNfL than those without (29.6pg/ml, IQR = 20.9-41.8; β = 1.461, p = 0.005 and β = 1.902, p = 0.002, respectively). sNfL was independently associated with Expanded Disability Status Scale (EDSS) assessments (β = 1.105, p < 0.001) and presence of relapses (β = 1.430, p < 0.001). sNfL levels were lower under disease-modifying treatment (β = 0.818, p = 0.003). Patients with sNfL levels above the 80th, 90th, 95th, 97.5th, and 99th HC-based percentiles had higher risk of relapses (97.5th percentile: incidence rate ratio = 1.94, 95% confidence interval [CI] = 1.21-3.10, p = 0.006) and EDSS worsening (97.5th percentile: OR = 2.41, 95% CI = 1.07-5.42, p = 0.034). INTERPRETATION: These results support the value of sNfL as a sensitive and clinically meaningful blood biomarker to monitor tissue damage and the effects of therapies in MS. Ann Neurol 2017;81:857-870.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Disanto G, Barro C, Benkert P, et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017. PMID: 28512753. doi:10.1002/ana.24954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。